Overview

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-25

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Tesaro, Inc.

Collaborator:

Gynecologic Oncology Group

Treatments:

Niraparib